René Michel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
René Michel has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
Michael J. Zorn
5 shared publicationsGerald J. Berry
Stanford University Medical Center
2 shared publicationsVictoria A. Marcus
McGill University and McGill University Health Center
2 shared publications- Alessandro Pedicelli
Division of Gastroenterology, McGill University Health Centre , Montreal, QC
1 shared publication - B. Ashok Reddy
Molecular Physiology Research Unit, Institut de Recherches Cliniques de Montréal, Montréal, Québec, Canada, H2W 1R7
1 shared publication - Benoit J. Arsenault
Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec - Université Laval, Québec, Canada; Department of Medicine, Faculty of Medicine, Université Laval, Québec, Québec, Canada
1 shared publication
Latest Publications
- Open Access
The vitamin K oxidoreductase VKORC1L1 prevents oxidative stress in hepatocytes and protects from MASLD and hepatocellular carcinoma
Generation of vitamin K hydroxyquinone (VKH 2 ) by vitamin K oxidoreductase 1 (VKORC1) is essential for the γ-carboxylation of clotting factors by hepatocytes. Here, we uncover a non-redundant function of the vitamin K oxidoreductase paralogue VKORC1L1 in liver homeostasis. Mice lacking Vkorc1l1 globally or specifically in hepatocytes exhibit normal coagulation yet develop progressive metabolic dysfunction–associated steatotic liver disease (MASLD). Transcriptomic profiling revealed early dysregulation of lipid metabolism and inflammatory pathways, converging on human MASLD signatures, while genetic colocalization analyses implicate human VKORC1L1 variants in MASLD and liver fat accumulation. Mechanistically, VKORC1L1 prevents reactive oxygen species overload and DNA damage through vitamin K reduction, independently of γ-carboxylation. Loss of VKORC1L1 induces oxidative stress, chromosome instability, and aneuploidy, culminating in steatohepatitic hepatocellular carcinoma (HCC). Conversely, pharmacological vitamin K supplementation rescues oxidative stress, MASLD and DNA damage in Vkorc1l1 -deficient mice. These findings redefine vitamin K as a hepatic antioxidant and identify VKORC1L1 as a safeguard against MASLD and HCC.
Open AccessThe vitamin K oxidoreductase VKORC1L1 prevents oxidative stress in hepatocytes and protects from MASLD and hepatocellular carcinoma
Generation of vitamin K hydroxyquinone (VKH 2 ) by vitamin K oxidoreductase 1 (VKORC1) is essential for the γ-carboxylation of clotting factors by hepatocytes. Here, we uncover a non-redundant function of the vitamin K oxidoreductase paralogue VKORC1L1 in liver homeostasis. Mice lacking Vkorc1l1 globally or specifically in hepatocytes exhibit normal coagulation yet develop progressive metabolic dysfunction–associated steatotic liver disease (MASLD). Transcriptomic profiling revealed early dysregulation of lipid metabolism and inflammatory pathways, converging on human MASLD signatures, while genetic colocalization analyses implicate human VKORC1L1 variants in MASLD and liver fat accumulation. Mechanistically, VKORC1L1 prevents reactive oxygen species overload and DNA damage through vitamin K reduction, independently of γ-carboxylation. Loss of VKORC1L1 induces oxidative stress, chromosome instability, and aneuploidy, culminating in steatohepatitic hepatocellular carcinoma (HCC). Conversely, pharmacological vitamin K supplementation rescues oxidative stress, MASLD and DNA damage in Vkorc1l1 -deficient mice. These findings redefine vitamin K as a hepatic antioxidant and identify VKORC1L1 as a safeguard against MASLD and HCC.
- 25 August 2025
- Published by Taylor & Francis in Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
- Vol. 9 (sup2)
Jim Hogg: Researcher and pathologist extraordinaire
- 25 August 2025
- Published by Taylor & Francis in Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
- Vol. 9 (sup2)
Jim Hogg: Researcher and pathologist extraordinaire
- Open Access
- 2 April 2024
- Published by Hindawi Limited in Case Reports in Hematology
- Vol. 2024, 1-5
Cytomegalovirus-Induced Hemophagocytic Lymphohistiocytosis in an Immunocompromised Patient with Inflammatory Bowel Disease
Hemophagocytic lymphohistiocytosis (HLH) is a rare and often fatal syndrome of immune hyperactivation, cytokine dysregulation, and severe inflammation. This severe syndrome is commonly triggered by infection, malignancy, autoimmunity, or immunosuppression. We present herein the case of a 56-year-old-female diagnosed with HLH triggered by an acute cytomegalovirus (CMV) infection with viremia in the context of immunosuppression for inflammatory bowel disease. This case highlights the importance of utilizing multiple diagnostic tools, prompt initiation of anti-hemophagocytic treatment, and management of the underlying etiology, to prevent significant morbidity and mortality.
- 2 April 2024
- Published by Hindawi Limited in Case Reports in Hematology
- Vol. 2024, 1-5
Open AccessCytomegalovirus-Induced Hemophagocytic Lymphohistiocytosis in an Immunocompromised Patient with Inflammatory Bowel Disease
Hemophagocytic lymphohistiocytosis (HLH) is a rare and often fatal syndrome of immune hyperactivation, cytokine dysregulation, and severe inflammation. This severe syndrome is commonly triggered by infection, malignancy, autoimmunity, or immunosuppression. We present herein the case of a 56-year-old-female diagnosed with HLH triggered by an acute cytomegalovirus (CMV) infection with viremia in the context of immunosuppression for inflammatory bowel disease. This case highlights the importance of utilizing multiple diagnostic tools, prompt initiation of anti-hemophagocytic treatment, and management of the underlying etiology, to prevent significant morbidity and mortality.
- Open Access
- 10 November 2022
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 31 (4) , 464-471
Breast Implanted-Associated Anaplastic Large Cell Lymphoma: A Case of Advanced Disease with Flow Cytometric Findings
Breast implant-associated anaplastic large cell lymphoma (breast implant-associated ALCL) is a recently described, distinct clinicopathological entity associated with macrotextured breast implants. The diagnostic workup of a patient suspected to have breast implant-associated ALCL includes cytological assessment of effusions and tissue biopsies of any masses or enlarged lymph nodes, with morphologic and immunophenotypic evaluation and possible flow cytometric and molecular testing. We report the case of a woman found to have breast implant-associated ALCL on fine needle aspirate and core biopsy, who on surgical resection, had extensive local disease with involvement of the resection margins and lymph nodes, requiring systemic treatment. We focus on the flow cytometric findings that identified a population of large cells on the CD30/side scatter dot plot and whose immunophenotype was consistent with breast implant-associated ALCL, highlighting the value of flow cytometry as an adjunct to morphological and immunophenotypic evaluation.
- 10 November 2022
- Published by SAGE Publications in International Journal of Surgical Pathology
- Vol. 31 (4) , 464-471
Open AccessBreast Implanted-Associated Anaplastic Large Cell Lymphoma: A Case of Advanced Disease with Flow Cytometric Findings
Breast implant-associated anaplastic large cell lymphoma (breast implant-associated ALCL) is a recently described, distinct clinicopathological entity associated with macrotextured breast implants. The diagnostic workup of a patient suspected to have breast implant-associated ALCL includes cytological assessment of effusions and tissue biopsies of any masses or enlarged lymph nodes, with morphologic and immunophenotypic evaluation and possible flow cytometric and molecular testing. We report the case of a woman found to have breast implant-associated ALCL on fine needle aspirate and core biopsy, who on surgical resection, had extensive local disease with involvement of the resection margins and lymph nodes, requiring systemic treatment. We focus on the flow cytometric findings that identified a population of large cells on the CD30/side scatter dot plot and whose immunophenotype was consistent with breast implant-associated ALCL, highlighting the value of flow cytometry as an adjunct to morphological and immunophenotypic evaluation.
- 1 August 2021
- Published by Wiley in Histopathology
- Vol. 79 (6) , 1072-1086
In‐situ follicular neoplasia: a clinicopathological spectrum
Aims In situ follicular neoplasia (ISFN) occurs in ≈2-3% of reactive lymph nodes and is currently set apart from “partial involvement by follicular lymphoma” (PFL). ISFN can progress to overt lymphoma, but precise parameters to assess this risk and its association with related diseases remain incompletely understood. This study proposes to explore these parameters. Methods and results We reviewed 11 cases of ISFN and 1 of PFL between 2003 and 2018. Ten patients had ISFN in lymph nodes, one in the spleen. H&E and immunohistochemical stains were reviewed. Involvement of follicles by ISFN was scored using a 3-tier scheme. Of 5 cases with low ISFN scores, one had chronic myelomonocytic leukemia, one mycosis fungoides and three were free of hematopoietic diseases. Among them, 4 are alive and one was lost to follow-up. Of the 6 ISFN cases with high scores, 2 had concurrent marginal zone lymphomas, 1 concurrent diffuse large B-cell lymphoma (DLBCL), 1 Castleman-like disease, another progressive transformation of germinal centers with IgG4-related disease, and 1 no hematopoietic disease; all are alive except one who died of concurrent DLBCL. The patient with PFL developed DLBCL 7 years after diagnosis. Conclusions Based on this limited series, we conclude that only cases with high scores are associated with an overt lymphoma or an abnormal lymphoid process, and that scoring may be a useful parameter to assess risk for associated lymphoma, deserving further study. We also carried out a comprehensive review of the literature.
- 1 August 2021
- Published by Wiley in Histopathology
- Vol. 79 (6) , 1072-1086
In‐situ follicular neoplasia: a clinicopathological spectrum
Aims In situ follicular neoplasia (ISFN) occurs in ≈2-3% of reactive lymph nodes and is currently set apart from “partial involvement by follicular lymphoma” (PFL). ISFN can progress to overt lymphoma, but precise parameters to assess this risk and its association with related diseases remain incompletely understood. This study proposes to explore these parameters. Methods and results We reviewed 11 cases of ISFN and 1 of PFL between 2003 and 2018. Ten patients had ISFN in lymph nodes, one in the spleen. H&E and immunohistochemical stains were reviewed. Involvement of follicles by ISFN was scored using a 3-tier scheme. Of 5 cases with low ISFN scores, one had chronic myelomonocytic leukemia, one mycosis fungoides and three were free of hematopoietic diseases. Among them, 4 are alive and one was lost to follow-up. Of the 6 ISFN cases with high scores, 2 had concurrent marginal zone lymphomas, 1 concurrent diffuse large B-cell lymphoma (DLBCL), 1 Castleman-like disease, another progressive transformation of germinal centers with IgG4-related disease, and 1 no hematopoietic disease; all are alive except one who died of concurrent DLBCL. The patient with PFL developed DLBCL 7 years after diagnosis. Conclusions Based on this limited series, we conclude that only cases with high scores are associated with an overt lymphoma or an abnormal lymphoid process, and that scoring may be a useful parameter to assess risk for associated lymphoma, deserving further study. We also carried out a comprehensive review of the literature.
- Open Access
- 1 April 2021
- Published by Elsevier in JAAD Case Reports
- Vol. 10, 130-131
Necrotic ulcers on the abdomen
- 1 April 2021
- Published by Elsevier in JAAD Case Reports
- Vol. 10, 130-131
Open AccessNecrotic ulcers on the abdomen
- 10 December 2020
- Published by Springer Nature
- p. 361-386
Pathology of Pancreas Transplantation
- Open Access
- 1 May 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (19) , e20106
Extranodal NK/T cell lymphoma and lymphomatoid granulomatosis in a patient with chronic lymphocytic leukaemia
Rationale: Richter syndrome (RS) defines the transformation of chronic lymphocytic leukemia (CLL) into a more aggressive lymphoma. Although the term RS is most often reserved for transformation of CLL into diffuse large B-cell lymphoma (DLBCL), and less frequently Hodgkin lymphoma , the list of cases with more variable presentations in the literature is growing. Patient concerns: A 71-year-old Caucasian man initially consulted an otolaryngologist for a 1-year history of nasal congestion. Diagnoses: The asynchronous occurrence of 2 rare angiocentric Epstein–Barr virus (EBV)-related lymphoproliferative disorders in a patient with CLL, specifically clonally related lymphomatoid granulomatosis (LYG), and an extranodal NK/T-cell lymphoma, nasal type, are described herein. Interventions: Radiation therapy and a regimen of cis-platinum were administered for the NK/T cell lymphoma, and ibrutinib for LYG. Outcomes: The patient remains in complete clinical remission 8 years after the diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and recurrent extranodal NK/T cell lymphoma, and 2 years after the diagnosis of clonally related LYG. Lessons: Although the precise pathogenesis of RS remains incompletely understood, various molecular alterations, in particular long-term immunosuppression, may lead to RS, similar to the causal link existing between non-Hodgkin lymphomas and HIV infection, and post-transplantation lymphoproliferative disorders. EBV infection is linked to the pathogenesis of several types of lymphomas and found in a subset of patients with RS; immunosuppression, in the context of CLL or other pathological conditions or pharmacological agents, can disrupt the fine balance between virus and the host immune system, and result in EBV-driven lymphoproliferations of B-, T-, or NK-cell origin. The findings of our literature review thus suggest that such non-diffuse large B-cell lymphoma , non-Hodgkin lymphoma CLL transformations, may be considered as rare variants of RS.
- 1 May 2020
- Published by Wolters Kluwer Health in Medicine
- Vol. 99 (19) , e20106
Open AccessExtranodal NK/T cell lymphoma and lymphomatoid granulomatosis in a patient with chronic lymphocytic leukaemia
Rationale: Richter syndrome (RS) defines the transformation of chronic lymphocytic leukemia (CLL) into a more aggressive lymphoma. Although the term RS is most often reserved for transformation of CLL into diffuse large B-cell lymphoma (DLBCL), and less frequently Hodgkin lymphoma , the list of cases with more variable presentations in the literature is growing. Patient concerns: A 71-year-old Caucasian man initially consulted an otolaryngologist for a 1-year history of nasal congestion. Diagnoses: The asynchronous occurrence of 2 rare angiocentric Epstein–Barr virus (EBV)-related lymphoproliferative disorders in a patient with CLL, specifically clonally related lymphomatoid granulomatosis (LYG), and an extranodal NK/T-cell lymphoma, nasal type, are described herein. Interventions: Radiation therapy and a regimen of cis-platinum were administered for the NK/T cell lymphoma, and ibrutinib for LYG. Outcomes: The patient remains in complete clinical remission 8 years after the diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and recurrent extranodal NK/T cell lymphoma, and 2 years after the diagnosis of clonally related LYG. Lessons: Although the precise pathogenesis of RS remains incompletely understood, various molecular alterations, in particular long-term immunosuppression, may lead to RS, similar to the causal link existing between non-Hodgkin lymphomas and HIV infection, and post-transplantation lymphoproliferative disorders. EBV infection is linked to the pathogenesis of several types of lymphomas and found in a subset of patients with RS; immunosuppression, in the context of CLL or other pathological conditions or pharmacological agents, can disrupt the fine balance between virus and the host immune system, and result in EBV-driven lymphoproliferations of B-, T-, or NK-cell origin. The findings of our literature review thus suggest that such non-diffuse large B-cell lymphoma , non-Hodgkin lymphoma CLL transformations, may be considered as rare variants of RS.
- 16 September 2016
- Published by Springer Nature
- p. 401-449
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cell transplantation offers patients the only prospect of long-term survival for a substantial variety of otherwise incurable malignant neoplasms as well as selected non-neoplastic conditions. This therapeutic modality, however, carries significant risks and is associated with a wide range of complications affecting not only the bone marrow but many organ systems, in particular by graft-versus-host disease. Patients before, during, and following stem cell transplantation thus require close monitoring and the pathologist is frequently implicated in this process. The aim of this chapter is to provide the pathologist with the tools required to interpret biopsies from these patients at all stages of the transplantation process. Following an overview of hematopoietic stem cell transplantation and graft-versus-host disease, the chapter will focus on the histopathologic findings of graft-versus-host disease and other complications in several organs and tissue including bone marrow, skin, lung, kidney, gastrointestinal tract and liver, with emphasis on the diagnostic criteria and approaches to graft-versus-host disease.
- 16 September 2016
- Published by Springer Nature
- p. 401-449
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cell transplantation offers patients the only prospect of long-term survival for a substantial variety of otherwise incurable malignant neoplasms as well as selected non-neoplastic conditions. This therapeutic modality, however, carries significant risks and is associated with a wide range of complications affecting not only the bone marrow but many organ systems, in particular by graft-versus-host disease. Patients before, during, and following stem cell transplantation thus require close monitoring and the pathologist is frequently implicated in this process. The aim of this chapter is to provide the pathologist with the tools required to interpret biopsies from these patients at all stages of the transplantation process. Following an overview of hematopoietic stem cell transplantation and graft-versus-host disease, the chapter will focus on the histopathologic findings of graft-versus-host disease and other complications in several organs and tissue including bone marrow, skin, lung, kidney, gastrointestinal tract and liver, with emphasis on the diagnostic criteria and approaches to graft-versus-host disease.
- 16 September 2016
- Published by Springer Nature
- p. 173-263
Liver Transplantation